Genome-wide association study identifies germline variants linked to overall survival in lung cancer patients, suggesting biomarkers for immunotherapy outcomes.
Key Points
Patients with minor alleles of specific variants experienced significantly worse overall survival (HR=5.1), emphasizing the importance of genetics in immunotherapy response.
A locus on chromosome 2 showed near genome-wide significance for overall survival with a p value of 6.3×10⁻⁸, although no associations were found for objective response rate or progression-free survival.
Using genome-wide association study methods, the study analyzed variants in lung cancer patients treated with immune checkpoint inhibitors to explore genetic influences on survival.
Findings indicate potential for germline variants as predictive biomarkers for immune checkpoint inhibitor efficacy, calling for further validation in larger studies.